Canaccord Genuity maintains a 'Neutral' rating on AngioDynamics (Nasdaq: ANGO), price target increased to $17.

Canaccord analyst says, "Our F2011 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE